about
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.Mislocalization of the E3 ligase, β-transducin repeat-containing protein 1 (β-TrCP1), in glioblastoma uncouples negative feedback between the pleckstrin homology domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and Akt.Disruption of the interface between the pleckstrin homology (PH) and kinase domains of Akt protein is sufficient for hydrophobic motif site phosphorylation in the absence of mTORC2Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling.Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and protein kinase C.CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth.HIF-1 signaling in drug resistance to chemotherapy.PIM kinase (and Akt) biology and signaling in tumors.PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.Strange Bedfellows: Nuclear Factor, Erythroid 2-Like 2 (Nrf2) and Hypoxia-Inducible Factor 1 (HIF-1) in Tumor Hypoxia.Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms.Importance of the stress kinase p38alpha in mediating the direct cytotoxic effects of the thalidomide analogue, CPS49, in cancer cells and endothelial cells.Insulin receptor substrate 1 is a substrate of the Pim protein kinases.CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis.Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors.Targeting CDK4/6 to oppose hypoxia-mediated therapeutic resistance.
P50
Q34676901-89F6C598-3F41-48BD-96B4-02418505BE47Q35011051-01AC7E87-65B3-44E6-A523-1F1E0F842FD3Q35604279-A1D45F39-F2E4-4425-AA9F-F7EF30B67AAAQ35763264-6D4CA224-B2E8-495C-8F1E-626594A3ED70Q36070528-4ECF7E9F-84D5-4E2E-955F-C4F08FFF25F9Q37200911-2E8B72C0-95DF-4B00-8163-D5665BBDB24DQ37521419-5D7FEA7D-7F57-4414-963B-3ACE88DD863BQ38204800-F370EC26-59BE-4F5F-8A9E-5458C615CEE9Q38370023-1524DB0E-1918-4A63-838F-6F0A6C53422FQ38769889-9191E915-B324-4719-BB99-F3D37D9D22BDQ39224142-E0101114-4455-4AA1-A0F1-EBD6DD1CEA9CQ40107095-2CCAF655-D906-4F39-BAC8-9E4359C9A7D9Q40272578-CEF3E91F-1EA4-41FB-9DB6-EB17096B606CQ41535057-B31FB18B-379E-4C4D-918F-2A9367473D84Q43234584-D389DE35-AD59-46C3-B24C-74791EE08DB2Q47294305-ABEAF3BB-7AE5-4A79-8A24-668FC28CD805Q55005865-B003FF83-88F5-4948-9BF4-36DD1B4A5E5B
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Noel A Warfel
@ast
Noel A Warfel
@en
Noel A Warfel
@es
Noel A Warfel
@nl
type
label
Noel A Warfel
@ast
Noel A Warfel
@en
Noel A Warfel
@es
Noel A Warfel
@nl
prefLabel
Noel A Warfel
@ast
Noel A Warfel
@en
Noel A Warfel
@es
Noel A Warfel
@nl
P106
P31
P496
0000-0001-6410-9011